Promoting a Healthier Tomorrow

Driving innovative research to improve treatment and outcomes
About Bohn Epidemiology
Bohn Epidemiology is a specialized consulting firm providing strategic guidance and epidemiology support to pharmaceutical and biotechnology companies.

The company was established in 2009, (formally, Rhonda L Bohn, LLC, renamed in 2016) in order to meet the new and growing needs for expert epidemiology consulting. Bohn Epidemiology’s success is a result of close collaboration with clients and the ability to provide insight and expertise to answer complex questions throughout the drug development process.

Bohn Epidemiology is a team of epidemiologists, statisticians, information specialists, data analysts and research assistants. Senior team members have doctorate degrees in epidemiology (or equivalent) with many having ten or more years of post-graduate experience.

Degrees in medicine, nursing, and pharmacy are also represented among senior staff. The company strives to match client needs with the most appropriate staff in relation to therapeutic area and methodologic expertise.

The company’s approach is to work with clients in an environment of transparency; team members work directly with clients to discuss their needs and provide guidance on the methodology needed to answer epidemiology questions related to signal detection, study design and execution, report content and preparation and ‘all matters epidemiology.’ The company’s strategic value resides in the team’s knowledge base, ability to provide quality deliverables, accessibility, and dedication to the company’s clients.

Not everything that can be counted counts, and not everything that counts can be counted.

—Albert Einstein

Background and Founding
Bohn Epidemiology was founded by Dr. Rhonda Bohn, a pharmacoepidemiologist with over 25 years of experience in the healthcare sector.

Dr. Bohn received her MPH from Yale University and ScD in Epidemiology from Harvard University. Prior to consulting, Rhonda worked in the private sector for pharmaceutical companies, consulting groups, and health insurers as well as spending ten years in academia where she was an Instructor in Medicine at the Brigham and Women’s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics.

Rhonda serves on Advisory Boards and Steering Committees for large-scale and multi-database studies representing clients and Medical Society Organizations. She has authored over 50 articles published in peer-reviewed journals and is a reviewer for many journals including Pharmacoepidemiology and Drug Safety, the Journal of Managed Care Pharmacy, Drug Safety, Thrombosis and Haemostasis, Pediatrics, and Haemophilia. She also served on the Editorial Board for Pharmacoepidemiology and Drug Safety from 2017-2018 and is an active member and Fellow of the International Society for Pharmacoepidemiology (ISPE) and served on its Board from 2014–2016.

Rhonda Headshot

Rhonda leads Bohn Epidemiology and is an active member of the research team. She ensures that the work delivered by the company exceeds client needs in terms of methodological and technical expertise as well as meeting timelines. In addition, Rhonda has strong relationships with academic groups and welcomes the opportunity to introduce her clients to both academic and industry experts.

Specialties include:​​ ​Pharmacoepidemiology, Drug Safety Studies, Health Outcomes Research, Risk Management and Evaluation, Use of Large Administrative and EMR Databases for Epidemiologic Research, Corporate Strategy

Bohn Epidemiology’s clientele includes large and small global pharmaceutical and biotech companies.

Within these companies, Bohn Epidemiology works with stakeholders throughout these companies including epidemiology, statistics, health economics, outcomes research, pharmacovigilance, clinical affairs, drug development, commercial, and marketing. Many of the company’s clients have Centers of Excellence (COE) and Real World Evidence (RWE) organizations. These interdisciplinary teams engage Bohn Epidemiology to collaborate on large projects requiring both strategic and project-focused work.

Portrait Handshake

Consulting Services

  • General

    Study design

    Protocol design and implementation

    Study operation and execution

    Report generation

    Manuscript preparation

    Database expertise including multisite collaborations


    Advisory board member (content and therapeutic area)

  • Therapeutic Area

    Rare diseases (hemophilia, cystic fibrosis, ALS, LSDs, others)






    Cardiovascular disease

  • Corporate

    Advise on integration of epidemiology services

    Business planning for epidemiology groups

    Establishment of and direction of clinical and Methodology advisory boards

    Initiate and participate in business collaborations and strategic partnerships

  • Drug Safety and Effectiveness

    Safety surveillance/monitoring studies

    Comparative effectiveness/ safety studies

    Safety endpoint validation studies

    Risk evaluation and mitigation studies

  • Natural History
    of Disease

    Literature reviews

    Disease characterization

    Burden of illness (incidence, prevalence)

    Database studies

  • Health Economics and Outcomes Research

    Pharmacoeconomic studies

    Compliance and persistence

    Healthcare utilization

Latest Publications

  • Bohn RL, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol 2018 Mar-Apr;36(2):263-274.
  • Gagne JJ, Rassen JA, Choudry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf 2014;37(3):151-161. 

  • Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc 2013;2(4):e000208. 

  • Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21(12):1350-1358. 

  • Bykov K, Bohn R, Ewenstein BM, et al. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors. Thromb Haemost 2017;117(12): 2267-2273.

Are you an organization, academic group or potential client interested in working together with Bohn Epidemiology? Contact Dr. Bohn directly at:

  1. Monday
  2. Tuesday
  3. Wednesday
  4. Thursday
  5. Friday
  6. Saturday
  7. Sunday
Copyright Bohn Epidemiology 2019 - Web Design by B12